| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/14737175.2017.1245616 |
| P8608 | Fatcat ID | release_entk2qg3xfezlcwtlvffv6fzhm |
| P698 | PubMed publication ID | 27718747 |
| P50 | author | Irene Moreno Torres | Q57035387 |
| P2093 | author name string | Antonio García-Merino | |
| P2860 | cites work | Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? | Q57041523 |
| Functional FCGR3A 158 V/F and IL-6 −174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis | Q57330337 | ||
| Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases | Q59273782 | ||
| Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. | Q51978495 | ||
| Neurosurgery: Quick check for tumour infiltration. | Q52147242 | ||
| The effects of intrathecal rituximab on biomarkers in multiple sclerosis. | Q52875864 | ||
| CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. | Q53173591 | ||
| Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. | Q53200046 | ||
| Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. | Q53555780 | ||
| Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. | Q55036043 | ||
| Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q24630092 | ||
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| Ofatumumab | Q24651912 | ||
| The Ins and Outs of B Cells in Multiple Sclerosis | Q26776542 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis | Q30446377 | ||
| B cells as antigen presenting cells | Q33238071 | ||
| Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation | Q33599648 | ||
| The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). | Q33654152 | ||
| Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis | Q33834491 | ||
| Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. | Q33849373 | ||
| Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity | Q33896738 | ||
| Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. | Q33899917 | ||
| Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis | Q34098936 | ||
| Early events in B cell activation | Q34101385 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report | Q34227269 | ||
| Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial | Q34229618 | ||
| Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination | Q34279716 | ||
| Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity | Q34287001 | ||
| Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis | Q34295012 | ||
| How B cells capture, process and present antigens: a crucial role for cell polarity | Q34353214 | ||
| Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis | Q34538912 | ||
| IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases | Q34658996 | ||
| Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein | Q34773444 | ||
| Immunoglobulins and complement in postmortem multiple sclerosis tissue | Q34937786 | ||
| Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. | Q35539775 | ||
| Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). | Q35557832 | ||
| Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients | Q35585366 | ||
| Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system | Q35760171 | ||
| Inflammatory cortical demyelination in early multiple sclerosis | Q35764685 | ||
| Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. | Q35858046 | ||
| Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. | Q39808939 | ||
| Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses | Q39868371 | ||
| Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. | Q40519355 | ||
| Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts | Q40695150 | ||
| AN ELECTROPHORETIC STUDY OF THE PROTEIN COMPONENTS IN CEREBROSPINAL FLUID AND THEIR RELATIONSHIP TO THE SERUM PROTEINS. | Q40973713 | ||
| Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies | Q41511541 | ||
| Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally | Q41874184 | ||
| Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties | Q41966195 | ||
| Depletion of B lymphocytes from cerebral perivascular spaces by rituximab | Q42458182 | ||
| Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial | Q42647640 | ||
| Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. | Q43227358 | ||
| Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial | Q45119459 | ||
| Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study | Q45890653 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis | Q47969566 | ||
| Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis | Q48162212 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. | Q48406120 | ||
| Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. | Q48427388 | ||
| Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders | Q48858718 | ||
| Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis | Q48949365 | ||
| Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis | Q48949792 | ||
| The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. | Q50739439 | ||
| BAFF suppresses IL-15 expression in B cells. | Q50855805 | ||
| MS arising during Tocilizumab therapy for rheumatoid arthritis. | Q50894215 | ||
| Epidemiology of multiple sclerosis. | Q50917635 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| B cell subsets in healthy children: reference values for evaluation of B cell maturation process in peripheral blood. | Q51051104 | ||
| Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. | Q51697140 | ||
| The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort | Q35864847 | ||
| A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface | Q35886917 | ||
| B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells | Q35946128 | ||
| Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production | Q35953204 | ||
| Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis | Q35986699 | ||
| B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity | Q36034499 | ||
| Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models | Q36059965 | ||
| CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation | Q36161486 | ||
| Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis | Q36190565 | ||
| Macrophages are critical effectors of antibody therapies for cancer | Q36213288 | ||
| Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins | Q36330016 | ||
| B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation | Q36485715 | ||
| B cell exchange across the blood-brain barrier in multiple sclerosis | Q36498036 | ||
| Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis | Q36639659 | ||
| IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis | Q36752491 | ||
| Specific peripheral B cell tolerance defects in patients with multiple sclerosis | Q36890946 | ||
| B-cell depletion and repopulation in autoimmune diseases | Q37083390 | ||
| MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies | Q37397820 | ||
| Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects | Q37565888 | ||
| CD20 as a target for therapeutic type I and II monoclonal antibodies. | Q37720878 | ||
| CD20-targeted therapy: the next generation of antibodies | Q37720891 | ||
| The evidence for a role of B cells in multiple sclerosis | Q37993033 | ||
| B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies | Q38097170 | ||
| The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review | Q38209230 | ||
| B cells in MS and NMO: pathogenesis and therapy | Q38212081 | ||
| B cells with immune-regulating function in transplantation | Q38213294 | ||
| B cell follicle-like structures in multiple sclerosis-with focus on the role of B cell activating factor. | Q38222302 | ||
| Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis | Q38375943 | ||
| FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts | Q38391516 | ||
| Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. | Q38545898 | ||
| The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. | Q38621895 | ||
| Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l | Q38827600 | ||
| Human memory B cells | Q38921183 | ||
| Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others | Q39157881 | ||
| P433 | issue | 4 | |
| P921 | main subject | monoclonal antibody | Q422248 |
| multiple sclerosis | Q8277 | ||
| P304 | page(s) | 359-371 | |
| P577 | publication date | 2016-10-10 | |
| P1433 | published in | Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders | Q15760319 |
| P1476 | title | Anti-CD20 monoclonal antibodies in multiple sclerosis | |
| P478 | volume | 17 |
| Q97427273 | Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? |
| Q90393310 | Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis |
| Q57822076 | G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis |
| Q42072531 | Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision |
| Q46408884 | Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents. |
| Q41430983 | IL-10-Producing B Cells Suppress Effector T Cells Activation and Promote Regulatory T Cells in Crystalline Silica-Induced Inflammatory Response In Vitro. |
| Q57470698 | Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis |
| Q92452801 | Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study |
| Q41660408 | Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review |
| Q58555322 | Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? |
| Q64904663 | Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin. |
| Q55234556 | Targeting B Cells and Plasma Cells in Autoimmune Diseases. |
| Q64085734 | Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions |
Search more.